Page 1

BIOMÉRIEUX bioMérieux - First - Half 2021 Results € 1,574 million in first - half 2021 sales , up 12.3 % like - for - like Q2 sales organic growth at 7.9 % in line with our expectations : slowdown in molecular biology , strong growth of immunoassays , and good momentum in microbiology and industrial applications Contributive operating income before non - recurring items up 48 % to € 374 million , or nearly 24 % of sales for the first half of the year 2021 guidance confirmation : bioMérieux confirms its annual guidance of organic sales growth at neutral to mid - single digit rate and contributive operating income before non - recurring items in line with 2020 . Alexandre Mérieux , Chairman and Chief Executive Officer , said : " bioMérieux achieved a solid performance in the first half of 2021 , in line with its expectations , both in terms of top line and profitability . We succeeded to launch several new solutions that are widening our offer dedicated to the fight against infectious diseases . We do confirm annual guidance of neutral to mid - single digit organic growth and contributive operating income before non - recurring items in line with 2020 " Marcy l'Etoile ( France ) , September 1 , 2021 - The Board of Directors of bioMérieux , a world leader in the field of in vitro diagnostics , met on August 31 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30 , 2021 . Consolidated data 2021 2020 In € millions % Change As reported Net Sales 1,574 1,476 + 6.6 % Contributing operating income before non- recurring items ( 1 ) 374 253 +47.8 % % sales 23.8 % 17.1 % Operating incomel ( 2 ) 366 232 + 57.6 % Net income , group share 277 173 + 60.3 % Diluted net income per share ( in € ) 2.33 € 1.46 € PRESS RELEASE ( 1 ) Contributive operating income before non - recurring items corresponds to operating income before non - recurring items relating to the BioFire acquisition . ( 2 ) Operating income is the sum of contributive operating income before non - recurring items , BioFire purchase price amortization expense and " material , extraordinary and non - recurring items " recognized in " Other non - recurring income and expenses from operations , net " .